Research programme: small-molecule nucleic acid therapeutics - Spring Bank Pharmaceuticals

Drug Profile

Research programme: small-molecule nucleic acid therapeutics - Spring Bank Pharmaceuticals

Alternative Names: Asthma and allergy therapeutics - Spring Bank; Cancer therapeutics - Spring Bank; COPD therapeutics - Spring Bank; SB 11177; SB 11179; SB 11285

Latest Information Update: 31 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Nucleic acids; Small molecules
  • Mechanism of Action Cyclic AMP phosphodiesterase inhibitors; Immunosuppressants; MPYS-protein-stimulants; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Hypersensitivity; Inflammation

Most Recent Events

  • 31 May 2018 Preclinical development in Cancer is ongoing in USA (PO)
  • 31 May 2018 Discontinued - Preclinical for Inflammation in USA (PO) (Spring Bank pipeline, May 2018)
  • 20 Feb 2018 Spring Bank Pharmaceuticals announces intention to submit an IND application and/or a clinical trial application for SB 11285 to the US FDA and/or EMA in 2H 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top